Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intravenous immunoglobulin therapy for antibody deficiency.

Literature DB >> 477026

Intravenous immunoglobulin therapy for antibody deficiency.

M T Nolte, B Pirofsky, G A Gerritz, B Golding.

Abstract

Twenty patients with antibody deficiency were treated at random with either intramuscular immune serum globulin (ISG) or intravenous modified immune serum globulin (M-ISG). Fourteen patients received of 259 M-ISG infusions during 242 months of treatment. Catastrophic vasomotor reactions were not observed. A single dose of 150 mg/kilo M-ISG increased serum IgG values a mean 248 mg%. Intravenous M-ISG therapy was effective in reducing the incidence of acute infections. Subjects receiving M-ISG developed 0.103 acute infections per month of treatment. Patients injected with ISG had 0.295 acute infections per month of treatment. Seven subjects had separate courses of both intravenous M-ISG and intramuscular ISG. Acute infections per month of treatment for M-ISG and ISG were 0.104 and 0.406, respectively.

Entities: Disease Species

Mesh：

Substances：

Year: 1979 PMID： 477026 PMCID： PMC1537711

Source DB: PubMed Journal: Clin Exp Immunol ISSN： 0009-9104 Impact factor: 4.330

16 in total

1. Intravenous administration of human gamma-globulin.

Authors: S BARANDUN; P KISTLER; F JEUNET; H ISLIKER
Journal: Vox Sang Date: 1962 Impact factor: 2.144

2. [On new possibilities of intravenous gamma globulin administration].

Authors: H E SCHULTZE; G SCHWICK
Journal: Dtsch Med Wochenschr Date: 1962-08-24 Impact factor: 0.628

3. The agammaglobulinemias; relations and implications.

Authors: C A DOMZ; D R DICKSON
Journal: Am J Med Date: 1957-12 Impact factor: 4.965

4. Agammaglobulinemia, congenital, acquired and transient forms.

Authors: D GITLIN; C A JANEWAY
Journal: Prog Hematol Date: 1956

5. Turnover of standard-gammaglobulin, pH-4-gammaglobulin and pepsin desaggregated gammaglobulin and clinical implications.

Authors: H Koblet; S Barandun; H Diggelmann
Journal: Vox Sang Date: 1967-07 Impact factor: 2.144

6. Studies with intravenous gamma globulin.

Authors: E Merler; F S Rosen; S Salmon; J D Crain; C A Janeway
Journal: Vox Sang Date: 1967-07 Impact factor: 2.144

7. Biologic activities of aggregated gamma-globulin. 8. Aggregated immunoglobulins of different classes.

Authors: T Ishizaka; K Ishizaka; S Salmon; H Fudenberg
Journal: J Immunol Date: 1967-07 Impact factor: 5.422

8. The preparation of plasmin treated immune serum globulin for intravenous use.

Authors: J T Sgouris
Journal: Vox Sang Date: 1967-07 Impact factor: 2.144

9. Uptake of IgG after intramuscular and subcutaneous injection.

Authors: G N Smith; B Griffiths; D Mollison; P L Mollison
Journal: Lancet Date: 1972-06-03 Impact factor: 79.321

10. Undegraded -globulin for intravenous therapy. A new preparation of immune serum globulin for intravenous administration.

Authors: W Stephan; M Hainski; J H Payne; G A Ordonez; E Shanbrom
Journal: Vox Sang Date: 1971-05 Impact factor: 2.144

34 in total

1. Efficacy and safety of subcutaneous vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study.

Authors: Michael Borte; Isabella Quinti; Annarosa Soresina; Eduardo Fernández-Cruz; Bruce Ritchie; Dirk S Schmidt; Christine McCusker
Journal: J Clin Immunol Date: 2011-09-20 Impact factor: 8.317

10. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases.

Authors: Hans D Ochs; Paul J Pinciaro
Journal: J Clin Immunol Date: 2004-05 Impact factor: 8.317

Intravenous immunoglobulin therapy for antibody deficiency.

1. Intravenous administration of human gamma-globulin.

2. [On new possibilities of intravenous gamma globulin administration].

3. The agammaglobulinemias; relations and implications.

4. Agammaglobulinemia, congenital, acquired and transient forms.

5. Turnover of standard-gammaglobulin, pH-4-gammaglobulin and pepsin desaggregated gammaglobulin and clinical implications.

6. Studies with intravenous gamma globulin.

7. Biologic activities of aggregated gamma-globulin. 8. Aggregated immunoglobulins of different classes.

8. The preparation of plasmin treated immune serum globulin for intravenous use.

9. Uptake of IgG after intramuscular and subcutaneous injection.

10. Undegraded -globulin for intravenous therapy. A new preparation of immune serum globulin for intravenous administration.

1. Efficacy and safety of subcutaneous vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study.

Review 2. Therapeutic strategies in common variable immunodeficiency.

Review 3. Clinical uses of intravenous immunoglobulin.

Review 4. Basic principles of intravenous immunoglobulin (IVIg) treatment.

5. Recommendations for the use of albumin and immunoglobulins.

6. The clinical use of intravenous immunoglobulin in pediatrics.

7. Haemophilus influenzae type b opsonins of intravenous immunoglobulins.

8. Iron status in hypogammaglobulinaemia.

Review 9. Intravenous immune globulin in primary immunodeficiency.

10. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases.